COVID-19 Clinical Trials
| Trials |
|---|
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19
in Hospitalized Adults ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients ho… ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients hospitalized with COVID-19 and requiring supplemental oxygen administered by low flow, high flow, or non-invasive mechanical ventilation. Hospitalized adults (>18 years) with symptoms suggestive of COVID-19 Illness of any duration and laboratory-confirmed SARS-CoV-2 infection within 14 days Requires low or high flow oxygen devices or non-invasive mechanical ventilation Has not received 5 or more doses of remdesivir as treatment for COVID-19 Has not receive 6mg or more of dexamethasone in one day, on more than one day in the past 7 days
NCT04280705 STU00212207 |
Positive Affect Regulation sKills (PARK) The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g… The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g., loss of income, shortages of daily essentials, etc.). The program consists of 8 skills aimed at increasing the daily experience of positive emotion to help individuals cope with whatever stress they might be experiencing. The skills are presented over the course of 5 weeks and after learning each skill by reading through content on our platform, there is the opportunity to practice the skill on the platform as well. •At least 18 years of age •Speaks and reads English •Able to access the online platform through their phone, a public device (i.e., at the library) or at home •Lives in US STU00212262 |
COVID-19 Convalescent Blood BioBank (SeroCore) Individuals will have blood drawn on enrollment as well as 6, 12 and 24 months later. Blood will be used for genetic testing to identify factors associated with disease severity and immunologic responses. Blood will be used to interrogate imm… Individuals will have blood drawn on enrollment as well as 6, 12 and 24 months later. Blood will be used for genetic testing to identify factors associated with disease severity and immunologic responses. Blood will be used to interrogate immunologic responses over time. Blood will be shared with other investigators to validate serologic testing assays and to facilitate vaccine development. |
NU COVID-19 INT20L02 - International registry on thoracic cancer patients with COVID 19 - TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) An early report of COVID-19 cases indicated that cancer patients had an increased risk of developing severe COVID-19-related symptoms compared to … An early report of COVID-19 cases indicated that cancer patients had an increased risk of developing severe COVID-19-related symptoms compared to COVID-19 patients without cancer. The purpose of this registry is to collect clinical information like symptoms, treatments, and outcomes of thoracic cancer patients (NSCLC, SCLS, MPM, and TETs) with COVID-19 to help develop risk assessment strategies and treatment recommendations for thoracic cancer patients. Participants 18 years or older who have a type of thoracic cancer; (Non-Small Cell Lung Carcinoma [NSCLC], Small CellLung Carcinoma [SCLC], Malignant Pleural Mesothelioma [MPM], or thymicepithelial tumor [TET]) and have also been diagnosed with COVID-19
STU00212311 |
NU COVID-19 MSK20H04: Examining COVID19 Course and Outcomes in Patients Previously Diagnosed with Chronic Lymphocytic Leukemia (CLL) This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior … This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter. Primary Aim: To determine the 28-daymortality rate from the time of COVID 19 diagnosis for CLL patients infectedwith SARS-CoV2 at MSKCC and other institutions. Secondary Aims: To describe baseline characteristics, prior and current CLL directed therapies, COVID19 clinical course and outcomes for CLL patients infected with SARS-CoV2. To examine relationships between CLL directed therapy and COVID19 disease course and outcomes. To examine current practices regarding management of CLL directed therapy in CLL patients infected with SARS-CoV2. |
Wearable sensor to monitor and track COVID-19-like signs and symptoms to develop better care strategies for COVID-19 pandemic Specific Aims:1. Develop a wearable sensor package to gather data on COVID-19-like signs andsymptoms such as elevated body temperature, respiratory parameters, heart rate ,cou… Specific Aims:1. Develop a wearable sensor package to gather data on COVID-19-like signs andsymptoms such as elevated body temperature, respiratory parameters, heart rate ,coughand gait.2. Create algorithms to monitor and track changes to COVID19-like signs and symptomsfor developing a better care and isolation strategies for COVID-19 pandemic |
Screening for Coronavirus Antibodies in Neighborhoods (SCAN) Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than… Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than others. By taking part, you will help us find out how many peoplein specific areas have been exposed to SARS-CoV-2, and if these antibodiesprotect people against re-infection. |
Effects of the COVID-19 Pandemic on Sexual and/or Gender Minority (SGM) Individuals and People with HIV (PWH) Let’s find out the pandemic’s impact on the LGBTQ+ community and those living with HIV - by taking this national survey from home! The goal is to understand how COVID-19 and the U.S. r… Let’s find out the pandemic’s impact on the LGBTQ+ community and those living with HIV - by taking this national survey from home! The goal is to understand how COVID-19 and the U.S. response impacts your community in order to help build better health care, policy, and support systems. - by taking this national survey from home! The goal is to understand how COVID- 19 and the U.S. response impacts your community in order to help build better health care, policy, and support systems. We are looking for people who are LGBTQ+ and/or people who are HIV-positive to be in this study. You must be 18 years of age or older and a current resident of the United States to participate. STU00212293 |
Circulating Endothelial Cells as Biomarkers of Cardiovascular Events in Patients with COVID-19 This study is recruiting patients who have been admitted to the hospital with a diagnosis of COVID-19. The purpose of this research study is to look at a new marker of inflammation that may predict worsenin… This study is recruiting patients who have been admitted to the hospital with a diagnosis of COVID-19. The purpose of this research study is to look at a new marker of inflammation that may predict worsening clinical parameters or severe disease in patients with COVID-19 |
NCICOVID: NCI COVID-19 in Cancer Patients Study (N-CCaPS):
A Longitudinal Natural History Study Thepurpose of this study is to collect blood samples, medical information, andcopies of medical images from patients who are being treated for cancer and haveCOVID-19. Researchers will use thesesampl… Thepurpose of this study is to collect blood samples, medical information, andcopies of medical images from patients who are being treated for cancer and haveCOVID-19. Researchers will use thesesamples, information, and images to answer questions about how cancer affectsCOVID-19 and how COVID-19 affects cancer treatment outcomes.
Oneof the future research studies we expect to do with these blood samples isgenomic or genetic sequencing. Thesesequencing studies will be done to try to find genetic traits that might mean aperson with cancer has a better or worse outcome when they are infected withCOVID-19. They will also look at whetherthere are genetic traits that might mean being infected with COVID-19 affectscancer treatment outcomes.
Participantswho have already tested positive or if a coronavirus test result comes back andis positive, researchers will collect blood samples, COVID-19 and cancertreatment and outcome information, and copies of medical images such ascomputerized tomography (CT) scans to use for future research on COVID-19 incancer patients. For participants who are waiting for the results of theircoronavirus test, researchers will collect information about your medicalhistory and cancer history, but will not collect any blood samples or medicalimages yet. If the test result comesback and is negative, you will stop being in the study and no furtherinformation will be collected, but we will do research using the information wehave already collected. Participants 18 years or older who are being treated for cancer and have COVID-19 will be enrolled.
NCT04387656 STU00213072 |
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. This study is being done … ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. This study is being done to rapidly and efficiently evaluate multiple potential therapeutics for COVID-19 in an outpatient setting. Duration of study: 28 days of intensive follow-up, followed by limited follow-up through 24 weeks.
–Fever or feeling feverish, cough, shortness of breath, sore throat, body or muscle pain, fatigue, headache,chills, nasal discharge or congestion, loss of taste or smell, nausea or vomiting, diarrhea
NCT04518410 STU00213144 |
COVID Prevention Trials Registry Afteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open th… Afteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open the consent and registry survey in your web browser by clickingthe link below: COVID PreventionTrials Registry Consent . If thelink above does not work, try copying the link below into your web browser: https://is.gd/NUVaccineStudy The NorthwesternCOVID Prevention Trials Registry is open to all adults who are interested inbeing contacted about upcoming COVID vaccine and other prevention studies. TheCOVID vaccine trials will enrollpersonswhoareatrisk of infection and COVID-19 disease. This· · · - - - Racial/ethnic groups such as African Americans, Latinx, and NativeAmericanpopulations. STU00213110 |
COVID-19 and Prenatal Experiences (COPE) Study We would love to hear about your feelings and concerns during this challenging time! You will take an online survey, learn more about research happening at Northwestern relating to COVID-19, and be provided with a COVID-19 resource list. Many women have … We would love to hear about your feelings and concerns during this challenging time! You will take an online survey, learn more about research happening at Northwestern relating to COVID-19, and be provided with a COVID-19 resource list. Many women have valued participating in research like this that helps doctors understand how to support and treat pregnant women and their infants in the future. Researchers from Northwestern are reaching out to pregnant women and mothers of infants younger than 6 months old who may be interested in sharing their experiences relating to COVID-19. STU00212610 |
COVID-19 TestUS an initiative of RADx AcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection) We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visi… We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visit to collect nasal swabs (less than one inch into each nostril) for new and standard tests. You will also complete surveys through a web browser, App on mobile device, or telephone interview with research staff. These surveys take approximately 30 minutes and they collect information on prior COVID-19 testing, COVID-19 exposures, demographics, and brief medical history. |
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19) This study is enrolling patients at Northwestern Memorial Hospital who have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) or coronavirus disease 2019 (COVID-19) and requir… This study is enrolling patients at Northwestern Memorial Hospital who have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) or coronavirus disease 2019 (COVID-19) and require oxygen support. Doctors at Northwestern University want to better understand if blocking a molecule in the blood, plasminogen activator inhibitor-1 (PAI-1), which is linked with inflammation, pulmonary disease and clotting, can improve outcomes for people with COVID-19. The medicine being used in this study, TM5614, is an investigational drug, which means it is not approved by the U.S. Food and Drug Administration (FDA). |
FLUVOXAMINE FOR EARLY TREATMENT OF COVID-19: A FULLY-REMOTE, RANDOMIZED PLACEBO CONTROLLED TRIAL STOP COVID Trial is a randomized controlled trial that aims to help slow the progression of COVID-19 symptoms in symptomatic patients in the United States. The study is contactless meaning vol… STOP COVID Trial is a randomized controlled trial that aims to help slow the progression of COVID-19 symptoms in symptomatic patients in the United States. The study is contactless meaning volunteers may participate without leaving their home. Medication and study supplies are delivered by a courier or shipped overnight. We hope our study will demonstrate whether or not taking a medication, fluvoxamine, will help to prevent worsening of symptoms and prevent hospitalization. You may be eligible if you:
You may be ineligible if you:
NCT04668950 STU00213714 |
Assessment of the Diagnostic Analyzer for Selective Hybridization (DASH) Point of Care Technology for Diagnosis of SARS-CoV-2 Infection We are studying an innovative technology for diagnosing COVID-19 that is simpler, quicker, and at the point-of-care in a clinic. You would be asked to fill out… We are studying an innovative technology for diagnosing COVID-19 that is simpler, quicker, and at the point-of-care in a clinic. You would be asked to fill out web-based forms/surveys on-line and then visit one of our clinical sites to have two nasal swabs collected from the front part of your nose by our study team. These swabs will then be tested on our new technology, called DASH, and on a standard laboratory-based PCR test for COVID-19 virus. We will be comparing how accurate and feasible our DASH test is compared to the standard PCR testing at diagnosing COVID-19. You will be compensated for you time and parking at the study visit. We are enrolling adults and children (10 years and older) with and without typical symptoms of COVID-19 who are willing to provide two nasal swab specimens for testing on our new technology and on a standard comparator. Participants must be willing to answer questions/surveys using a web-based on-line system and come to one of our clinical sites for a single visit to have two nasal swabs collected. STU00213905 |